Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396808 · ClinicalTrials.gov registry record · NA
Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
A NA study of Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 900
- Enrollment target
- 8
- Study locations
NCT04396808: Recruiting NA study of Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center.
NCT04396808 is a NA study of Prostate Cancer that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 900 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% higher). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04396808, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 900 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
Conditions Studied
Interventions
- DEVICE Decipher
- DEVICE Prolaris
- DEVICE Oncotype Dx Genomic Prostate Score (GPS)
- OTHER Standard of care (askMUSIC score)
Study Locations (8)
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
- Henry Ford Health System - Detroit
- Sherwood Medical Center - Detroit
- Spectrum Health Medical Group - Grand Rapids
- Western Michigan Urological Associates - Holland
New York
- Montefiore Medical Center - The Bronx
North Carolina
- University of North Carolina - Chapel Hill
Pennsylvania
- University of Pennsylvania Perelman School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2031-04-30 |
| Phase | NA |
What NCT04396808 shows while recruiting
NCT04396808 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Decipher is the first listed.
NCT04396808 lists 8 locations in 4 states (Michigan, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT04396808 about?
NCT04396808 is a clinical study titled "Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer". This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.
What is the current status of trial NCT04396808?
This trial is currently recruiting. It is a NA study. The enrollment target is 900 participants. The study started on 2020-11-05. Estimated completion is 2031-04-30.
What conditions does trial NCT04396808 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04396808?
The interventions under investigation include: Decipher (DEVICE), Prolaris (DEVICE), Oncotype Dx Genomic Prostate Score (GPS) (DEVICE), Standard of care (askMUSIC score) (OTHER).
Who is sponsoring clinical trial NCT04396808?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04396808 being conducted?
This trial has 8 study locations across Michigan, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04396808's enrollment target sits among peer trials
900 72nd of 735 higher than 663 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT03932786 · 900 participants
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI